These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15232767)

  • 1. On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).
    Bancalari E
    Am J Perinatol; 2004 Jul; 21(5):307-9. PubMed ID: 15232767
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
    Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
    J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
    Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
    J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Oguz SS; Dilmen U
    J Paediatr Child Health; 2013 Dec; 49(12):1084. PubMed ID: 24325724
    [No Abstract]   [Full Text] [Related]  

  • 7. In response to mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Egan EA
    J Perinatol; 2013 Feb; 33(2):165-6. PubMed ID: 23361501
    [No Abstract]   [Full Text] [Related]  

  • 8. Complications among premature neonates treated with beractant and poractant alfa.
    Gharehbaghi MM; Sakha SH; Ghojazadeh M; Firoozi F
    Indian J Pediatr; 2010 Jul; 77(7):751-4. PubMed ID: 20589459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
    Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
    Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
    Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
    Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
    Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
    Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study.
    Lamboley-Gilmert G; Lacaze-Masmonteil T;
    Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
    Jeon GW; Oh M; Sin JB
    Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
    Malloy CA; Nicoski P; Muraskas JK
    Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome.
    Mirzarahimi M; Barak M
    Pak J Pharm Sci; 2018 Mar; 31(2):469-472. PubMed ID: 29618436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exogenous pulmonary surfactants on mortality rate in neonatal respiratory distress syndrome: A network meta-analysis of randomized controlled trials.
    Zhang L; Cao HY; Zhao S; Yuan LJ; Han D; Jiang H; Wu S; Wu HM
    Pulm Pharmacol Ther; 2015 Oct; 34():46-54. PubMed ID: 26296793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
    Ramanathan R; Biniwale M; Sekar K; Hanna N; Golombek S; Bhatia J; Naylor M; Fabbri L; Varoli G; Santoro D; Del Buono D; Piccinno A; Dammann CE
    J Pediatr; 2020 Oct; 225():90-96.e1. PubMed ID: 32553868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Two Different Exogenous Surfactant Preparations on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants with Severe Respiratory Distress Syndrome.
    Terek D; Gonulal D; Koroglu OA; Yalaz M; Akisu M; Kultursay N
    Pediatr Neonatol; 2015 Aug; 56(4):248-55. PubMed ID: 25603725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study.
    Ramanathan R; Bhatia JJ; Sekar K; Ernst FR
    J Perinatol; 2013 Feb; 33(2):119-25. PubMed ID: 21886094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
    Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
    Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.